In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

Clinical and Experimental Metastasis

Volumn 14, Issue 3, 1996, Pages 219-229

  Verbik, David J ^a   Stinson, Warren W ^a   Brunda, Michael J ^c   Kessinger, Anne ^b   Joshi, Shantaram S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Antitumor effects; Immune augmentation; Interleukin 12; Residual lymphoma

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER METASTASIS; LYMPHOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOPHENOTYPING; INTERLEUKIN-12; INTERLEUKIN-2; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHOMA; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; ORGAN SIZE; SPLEEN; STEM CELLS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0030059125     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Petersen FF, Appelbaum R and Hill, 1990, Autologous marrow transplantation for malignant lymphoma; a report of 101 cases from Seattle. J Clin Oncol, 8, 638-47.
2. Appelbaum F, 1988, Intensive chemotherapy or chemoradiotherapy with autologous marrow support as treatment for patients with solid tumors. Hematol/Oncol Clin North Am, 2, 345-51.
3. Arceci JR, 1993, Clinical significance of p-glycoprotein in multidrug resistant malignancies. Blood, 81, 2215-22.
4. Stern AS, Podlaski FJ, Hulmes JD, et al. 1990, Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblast cells. Proc Natl Acad Sci. USA, 87, 6808-12.
5. Kobayashi M, Fitz L, Ryan M, et al. 1989, Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med, 170, 827-45.
6. Gately MK, Wolitzky AG, Quinn PM and Chizzonite R, 1992, Regulation of human cytolytic lymphocyte response by interleukin-12. Cell Immunol, 143, 127-42.
7. + NK cells. J Immunol, 148, 2429-36.
8. Gately MK, Warrier RR, Honasoge S, et al. 1994, Administration of recombinant IL-12 to normal mice enhances cytolytic activity and induces production of IFN-γ in vivo. Int Immunol, 6, 157-67.
9. + Th 1 cells. Science, 263, 235-7.
10. Sieling PA, Wang HX, Gately MK, et al. 1994, IL-12 regulates T helper type 1 cytokine response in human infectious disease. J Immunol, 153, 3639-47.
11. Jackson JD, Yan Y, Brunda MJ, Kelsey LS and Talmadge JE, 1995, IL-12 enhances peripheral hematopoiesis in vivo. Blood, 85, 2371-6.
12. Ploemacher RE, van Soest PL, Voorwinden H and Boudewijn A, 1993, Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture. Leukemia, 7, 1381-8.
13. Gately MK, Gubler U, Brunda MJ, et al. 1994, Interleukin-12: a cytokine with therapeutic potential in oncology and infectious disease. Ther Immunol, 1, 187-93.
14. Brunson KW and Nicolson GL, 1979, Selection and biological properties of malignant variants of a murine lymphosarcoma. J Natl Cancer Inst, 61, 1499-503.
15. Joshi S, Tilden P, Jackson J, Sharp J and Brunson K, 1987, Cell surface properties associated with malignancy of metastatic large cell lymphoma cells. Cancer Res, 47, 3351-7.
16. Verbik DJ, Jackson JD, Pirruccello SJ, Patil KD, Kessinger A and Joshi SS, 1995, Functional and phenotypic characterization of human peripheral blood stem cell harvests: A comparative analysis of cells from consecutive collections. Blood, 85, 1964-70.
17. Pross F, Bains M, Rubin P, Shargge P and Patterson M, 1981, Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol, 1, 51-63.
18. Verbik DJ and Joshi SS, 1995, Immune cells and cytokines: Their role in cancer immunotherapy. Int J Oncology, 7, 205-24.
19. Mazumder A and Rosenberg SA, 1984, Successful immunotherapy of NK-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med, 159, 495-507.
20. LaFreniere R and Rosenberg SA, 1985, Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukin-2. Cancer Res, 45, 3735-41.
21. Rosenberg SA, Lotze MT, Muul LM, et al. 1987, A progressive report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med, 316, 889-97.
22. Lister J, Rybka WB, Donnenberg AD, et al. 1995, Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate post-transplant period. Clin Cancer Res, 1, 607-11.
23. Neta R, Stiefel SM, Finkelman F, Herrmann S and Ali N, 1994, IL-12 protects bone marrow from and sensitizes intestinal tract to ionizing radiation. J Immunol, 153, 4230-7.
24. Nastala CL, Edington HD, McKinney TC, et al. 1994, Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol, 153, 1697-706.
25. Gazzinelli RT, Wysocka M, Hayashi S, et al. 1994, Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol, 153, 2533-43.
26. Skorski T, Kawalec M, Hoser G, Ratajczak M, Gnatowski B and Kawiak J, 1988, The kinetics of immunologic and hematologic recovery in mice after lethal total body irradiation and reconstitution with syngeneic bone marrow cells treated or untreated with mafosfamide (ASTAZ 7654). Bone Marrow Transplant, 3, 543-51.
27. Yanagida T, Kato T, Igarashi O, Inoue T and Nariuchi H, 1994, Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol, 152, 4919-28.
28. Trinchieri G, 1995, Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. In: Paul W, Fathman CG and Metzger H, eds. Annual Review of Immunol. Palo Alto, CA, Annual Review Inc, pp. 251-76.
29. Jacobsen SE, Veiby OP and Smeland EB, 1993, Cytotoxic lymphocyte maturation factor (interleukin-12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med, 178, 413-18.
30. Siefer AK, Longo DL, Harrison CL, Reynolds CW and Murphy WJ, 1993, Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. Blood, 82, 2577-84.
31. Brunda MJ, Luistro L, Warner RR, et al. 1993, Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med, 178, 1223-30.